Interstitial lung diseases (ILDs) represent a heterogeneous group of over 200 chronic lung disorders characterized by inflammation and fibrosis of the lung interstitium. This article provides a comprehensive overview of ILDs, focusing on their pathogenesis, clinical manifestations, diagnostic approaches, and management strategies.
The etiology of ILDs is diverse, with causes ranging from environmental exposures to systemic diseases and genetic disorders. Irrespective of the cause, the common pathological hallmark is damage to the lung interstitium, leading to impaired gas exchange. Clinically, patients typically present with progressive dyspnea and non-productive cough. Physical examination may reveal crackles, clubbing, and signs of pulmonary hypertension in advanced stages.
The diagnostic evaluation of ILDs involves a combination of clinical, radiological, and histopathological findings. High-resolution computed tomography (HRCT) is the cornerstone of radiological assessment, displaying characteristic patterns that can suggest specific ILD subtypes. Pulmonary function tests demonstrate a restrictive pattern with reduced diffusion capacity for carbon monoxide. In certain cases, surgical lung biopsy may be warranted to establish a definitive diagnosis.
Management of ILDs is primarily aimed at slowing disease progression and improving quality of life. This typically involves removal of the inciting agent, use of immunomodulatory drugs, and, in some cases, lung transplantation. Novel antifibrotic agents have shown promise in reducing disease progression in idiopathic pulmonary fibrosis, one of the most common and severe forms of ILD. Pulmonary rehabilitation and supportive care remain integral to patient management.
ILDs pose a significant clinical challenge due to their diverse etiology, complex pathogenesis, and variable clinical course. A comprehensive understanding of these disorders is crucial for their timely diagnosis and appropriate management. Ongoing research into the underlying mechanisms and novel therapeutic strategies holds promise for improving patient outcomes in the future.
1.
Trial Supports Ivonescimab and Chemo for NSCLC Survival
2.
Cancer "Tidal Wave" Prediction: Not Cigarette-Based, Either! Wary Stories Regarding Cannabis and Cancer.
3.
Lymph node transfer reduces arm swelling after breast cancer surgery, study shows
4.
Silibinin is a novel and ancient molecule that highlights the significance of integrated therapies for cancer.
5.
Research Indicates that First-Line Immunotherapy Is Enough for Elderly NSCLC Patients?
1.
Unlocking the Power of Hematocrit: Exploring the Benefits of Blood Cell Counts
2.
Unpacking Chordoma: Understanding the Rare Cancer and its Treatment Options
3.
Colorectal Cancer Incidence Trends: A Growing Concern in 2024 and 2025
4.
Uncovering the Mysteries of the RDW Blood Test
5.
The Basics of Langerhans Cell Histiocytosis: Understanding a Rare Disease
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Complexities of Ph Negative ALL - Part II
2.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management
3.
Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment
4.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
5.
Navigating the Complexities of Ph Negative ALL - Part XIV
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation